4D-150

Age-related macular degeneration is a spectrum of macular disorders with atrophic and neovascular late stages. About 80% of people with AMD have the non-neovascular form, but the neovascular form accounts for nearly 90% of the severe visual acuity loss (20/200 or worse) caused by AMD, and AMD accounts for an estimated 46% of severe visual loss in people older than 40 years in the United States. In 2019, an estimated 1.49 million people aged 40 years or older in the United States had late-stage AMD (crude prevalence 0.94%) and 18.34 million had early-stage AMD (11.64%). An earlier estimate for 2000 put the prevalence of neovascular AMD or geographic atrophy at 1.47% of the US population aged 40 years or older, or 1.75 million people. Globally, pooled prevalence mapped to ages 45 to 85 years was 0.37% for late AMD and 8.69% for any AMD, corresponding to 196 million people with AMD in 2020 and a projected 288 million in 2040. In the United States, annual incidence of late AMD in White Americans aged 50 years or older was estimated at 3.5 per 1,000 (about 293,000 new cases per year), of which neovascular AMD accounted for 1.8 per 1,000, and incidence was 38% higher in women than men; among Medicare beneficiaries aged 65 years or older, 3-year incidence of exudative AMD was 9.4 to 11.4 per 1,000. In Europe, pooled annual incidence of any late AMD was 1.4 per 1,000, with incident cases projected to rise from about 400,000 to about 700,000 per year by 2050. In untreated unilateral disease, neovascular AMD developed in the fellow eye in 12.2% of patients by 12 months and 26.8% by 4 years.

Untreated neovascular AMD progresses to severe central vision loss. In a synthesis of untreated cohorts, mean visual acuity fell by 2.7 lines at 12 months and 4 lines at 24 months, the proportion of patients losing more than 6 lines rose from 21.3% at 6 months to 41.9% at 3 years, and the proportion with acuity worse than 20/200 rose from 19.7% at baseline to 75.7% at 3 years. Macular atrophy developed after untreated neovascular AMD in 9.6% of eyes at 2 years, 31.4% at 5 years, 43.1% at 7 years, and 61.5% at 10 years, a linear risk of about 6.5% per year. Globally in 2020, an estimated 1.85 million people were blind and 6.23 million had moderate or severe vision impairment because of AMD, and the number with AMD-related vision impairment rose from 3.64 million in 1990 to 8.06 million in 2021, with a projection of about 21.34 million in 2050; disability-adjusted life-years attributable to AMD rose by 91%, from 0.30 million to 0.58 million. After anti-VEGF therapy became available, the incidence of legal blindness attributable to AMD in people aged 50 years or older fell by 50%, from 52.2 to 25.7 cases per 100,000 per year between 2000 and 2010. Late AMD is associated with higher mortality: meta-analyses report hazard ratios of 1.20 (95% CI 1.02 to 1.41) and 1.23 (1.11 to 1.36) for all-cause mortality and 1.46 (1.13 to 1.98) and 1.28 (1.04 to 1.57) for cardiovascular mortality, whereas early AMD is not associated with either outcome.

Treatment changes but does not normalize the long-term course. At 5 years in the CATT cohort, 50% of eyes had acuity of 20/40 or better and 20% had 20/200 or worse, with mean change of -3 letters from baseline and -11 letters from the 2-year value; geographic atrophy was present in 213 of 515 gradable eyes (41%). Cumulative incidence of geographic atrophy among 1,011 participants without it at baseline was 12% at 1 year, 17% at 2 years, and 38% at 5 years, and the cumulative proportion of eyes with a fibrotic scar was 32%, 46%, and 56% at years 1, 2, and 5. At a mean of 7.3 years after entry into the pivotal ranibizumab trials, 37% of study eyes had acuity of 20/70 or better and 37% had 20/200 or worse, and macular atrophy was detected in 98% of eyes. Routine care produces smaller gains than trials: among 49,485 treatment-naive eyes in a United States database, a mean of 7.3 injections in the first year produced a mean gain of 0.95 letter, and in an 8-country study mean injections fell from 5.0 in year 1 to 2.2 in year 2 with mean gains of +2.4 and +0.6 letters. Of 162,902 eyes in United States practice, 34.3% presented with acuity of 20/40 or better at diagnosis.

The humanistic burden tracks vision in the better-seeing eye. Time trade-off utility values fell from 0.89 in patients with 20/20 to 20/25 vision to 0.40 in those with 20/800 to no light perception, and patients in the worst group were willing to trade 60% of their remaining lifetime for perfect vision, compared with 11% in the best group. Depressive symptoms have been reported in 15.7% to 44% of people with AMD and anxiety symptoms in 9.6% to 30.1%; in one anti-VEGF clinic cohort, 56% of 132 patients reported treatment-related anxiety, 17% had clinical levels of anxiety, and 12% had clinical levels of depression. Charles Bonnet syndrome was found in 15.8% of patients overall and 7.2% of consecutively recruited clinic patients with neovascular AMD. Impairment of basic, instrumental, and total activities of daily living was reported in 37.76%, 67.82%, and 39.59% of participants in one cohort, and AMD was associated with an increased risk of falls (hazard ratio 1.25, 95% CI 1.23 to 1.27) and fractures (1.18, 1.15 to 1.21).

Direct and societal costs are substantial and rise as vision worsens. In a commercially insured United States population, mean annual all-cause cost was $24,520 for prevalent and $18,943 for incident patients, with neovascular AMD-related outpatient costs accounting for 28% of the total; patients had a mean of 6.6 disease-related outpatient visits and 3.9 anti-VEGF-related visits per year. Mean annual societal cost was $39,910 in patients with neovascular AMD versus $6,116 in controls, ranging from $20,339 in the best-vision subcohort to $82,984 in the worst, and direct nonmedical costs, primarily caregiving, made up 67.1% of societal ophthalmic costs. Medicare spent an average of $9,719 and $9,934 per year on each beneficiary receiving ranibizumab and aflibercept injections, and the two agents accounted for 12% of the annual Medicare Part B budget. The total economic burden of vision loss in the United States was estimated at $134.2 billion, $98.7 billion direct and $35.5 billion indirect, or $16,838 per affected person per year. Caregivers carry part of this burden: an average clinic visit takes 90 minutes, but patients report almost 12 hours per visit including 66 minutes of travel and 9 hours of recovery, and caregivers took time away from work (22%) and personal activities (28%) to provide transportation. Caregivers provided support a mean of 4.2 days per week and 6.0 hours per day, 45.6% reported impairment in daily activities, and 70.5% of 44 working caregivers reported work absenteeism because of treatment and monitoring appointments. Most caregivers were a child or grandchild (47%) or partner (23%) and only 7% were professional caregivers, and 16% of patients missed a clinic visit; mean caregiver burden on the Caregiver Reaction Assessment was 3.2.

4D-150 is an investigational intravitreal adeno-associated virus gene therapy given as a single injection. It uses the synthetic R100 capsid, evolved in nonhuman primates for intravitreal delivery to the retina, and carries two transgenes: a codon-optimized sequence encoding aflibercept, which inhibits VEGF-A, VEGF-B, and PlGF, and a microRNA that inhibits expression of VEGF-C. The dose taken into phase 3 is 3E10 vg/eye. Clinical evidence comes from PRISM (NCT05197270), a phase 1/2 trial with several cohorts: a phase 1 dose exploration (15 participants, 5 each at 3E10, 1E10, and 6E9 vg/eye), a randomized phase 2a dose expansion (51 participants randomized 2:2:1 to 3E10 vg/eye [20 participants], 1E10 vg/eye [21], or aflibercept 2 mg every 8 weeks [10]), and an open-label phase 2b population extension (45 participants; 30 at 3E10 vg/eye and 15 at 1E10 vg/eye). In total, 71 participants have received the phase 3 dose. Two phase 3 trials are fully enrolled but have reported no results: 4FRONT-1 (523 participants randomized, North America, treatment-naive) and 4FRONT-2 (more than 500 participants expected, 14 countries, including up to 40% previously treated). Both compare a single injection of 4D-150 with aflibercept 2 mg every 8 weeks for noninferiority in mean BCVA change at 52 weeks, with supplemental aflibercept allowed in both arms.

Injection burden is the outcome on which 4D-150 has been reported most consistently. In the phase 2b cohort at 2 years (data cutoff May 18, 2026), the 30 participants at 3E10 vg/eye received a mean of 2.7 supplemental injections, a 78% reduction versus the 12.0 injections projected for on-label aflibercept 2 mg every 8 weeks, with 46% injection-free and more than 50% receiving 0 or 1 injection; the 15 participants at 1E10 vg/eye received a mean of 3.7 injections (69% reduction). In the recently diagnosed subgroup at 3E10 vg/eye (15 participants), the mean was 1.6 injections (87% reduction) and 66% were injection-free. At week 52 the same 3E10 vg/eye cohort had a mean of 0.97 injections (83% reduction versus 6.0 projected), 70% with 0 or 1 injection, and 57% injection-free, and the recently diagnosed subgroup had 0.33 injections (94% reduction) and 80% injection-free; the reduction at 3E10 vg/eye fell from 83% at 1 year to 82% at 1.5 years and 78% at 2 years. In the randomized phase 2a dose expansion at 24 weeks (data cutoff January 19, 2024), the annualized anti-VEGF injection rate fell 89% at 3E10 vg/eye (20 participants), with 84% receiving 0 or 1 injection and 63% injection-free, and 85% at 1E10 vg/eye (21 participants), with 90% and 50%. In the pooled phase 1/2a population at 3E10 vg/eye (24 participants), reduction versus each participant's injections in the prior 12 months was 83% through year 1 and 79% through year 2 (data cutoff August 22, 2025). In the phase 1 dose exploration, 4 of 5 participants (80%) at 3E10 vg/eye were injection-free at 24 weeks, and the 3 participants injection-free beyond 52 weeks remained so through about 2 to 2.5 years.

Vision results are smaller in magnitude and less certain. The only comparison with a concurrent aflibercept arm is the phase 2a dose expansion at 24 weeks: the adjusted mean BCVA difference versus aflibercept 2 mg every 8 weeks (10 participants), averaged over weeks 20 and 24, was -1.8 letters (95% CI -7.6 to 4.1) at 3E10 vg/eye and +1.8 letters (95% CI -3.8 to 7.4) at 1E10 vg/eye, and the CST differences were -8.3 µm and +29.9 µm; every interval includes zero, and the cohort was powered for injection counts rather than acuity. In the phase 2b cohort, mean BCVA change at week 52 was +2.2 letters with censoring of assessments confounded by cataract or surgery and +1.0 letter without censoring, with a mean CST change of -11 µm; the recently diagnosed subgroup had +3.1 letters and -10 µm. At 24 weeks in the phase 2b cohort, adjusted mean BCVA change was +3.5 letters (95% CI 1.1 to 5.8) at 3E10 vg/eye and -2.2 letters (95% CI -5.9 to 1.4) at 1E10 vg/eye. Two-year BCVA and CST were described as maintained, with values presented only in figures. In the phase 1 cohort at 3E10 vg/eye, mean BCVA was 1 letter above baseline and mean CST 110 µm below baseline through about 2 years.

Reported safety at the phase 3 dose is based on 71 participants. Within approximately the first 28 weeks after dosing, 2 of 71 (2.8%) had 4D-150-related 1+ mild intraocular inflammation, described as transient vitreous cells at a single timepoint, and no new cases were reported thereafter with 2 to more than 4 years of follow-up as of the July 2026 data cutoff. No 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive or non-occlusive retinal vasculitis, or choroidal effusions have been observed, and no 4D-150-related serious adverse events have been reported. Seventy of 71 participants (99%) completed the approximately 20-week prophylactic topical corticosteroid taper on schedule and 70 of 71 (99%) remained completely off steroids. One case of endophthalmitis, presumed bacterial, was attributed to a supplemental aflibercept injection rather than to 4D-150. At the lower 1E10 vg/eye dose in the phase 2b cohort, 1 of 15 participants (1 of 45 in that cohort, about 2%) had mild to moderate vitreous inflammation, with vitreous cells also observed in the untreated fellow eye. Frequency tables for treatment-emergent adverse events have not been released.

No randomized phase 3 results exist for 4D-150, and no peer-reviewed full publication of PRISM was identified; all results come from company announcements and congress presentations. The phase 2b cohort was single-arm and open-label, and its burden reduction was measured against a projected on-label aflibercept schedule (6.0 injections at 52 weeks and 12.0 at 2 years) derived from a single-arm model rather than against observed injections in a comparator arm, while phase 1 and phase 2a burden reduction was measured against each participant's injection count in the prior 12 months. Sources disagree on several values. For the phase 2b cohort at 52 weeks, a September 2024 Kaplan-Meier analysis reported an 89% reduction with 80% receiving 0 or 1 injection and 70% injection-free, whereas the January 2025 cutoff reported 83%, 70%, and 57%. For the phase 3-eligible subgroup of the phase 2a dose expansion, the company announcement reported a BCVA difference of +3.3 letters versus aflibercept while the congress slides for the same subgroup show +2.4 letters. The inflammation-free follow-up interval was described as approximately 1.5 to more than 3.5 years in the November 2025 announcement and as 2 to more than 4 years in the July 2026 announcement. Topline 52-week results are expected in the second quarter of 2027 for 4FRONT-1 and the second half of 2027 for 4FRONT-2.

No price, average sales price, wholesale acquisition cost, cost-effectiveness analysis, budget impact model, or health technology assessment has been published for 4D-150, and no published analyst price estimate was identified. The sponsor has not disclosed a price and has stated that 4D-150 would likely be priced well above a single intravitreal anti-VEGF injection, that retina clinics largely fit the Medicare Part B buy-and-bill model, and that the relatively low doses required allow pricing flexibility through favorable cost of goods sold. The sponsor estimates the 2025 global branded retinal vascular disease anti-VEGF market at $16 billion, of which about $10 billion is wet AMD and about $4 billion is diabetic macular edema, and reports that more than 600,000 United States patients receive regular anti-VEGF therapy across more than 800,000 eyes; under the Otsuka license the Asia-Pacific territory represents about 10% of the global retinal anti-VEGF market, and the sponsor retains about 85% of the commercial potential of 4D-150. Budget impact for 4D-150 therefore cannot be estimated from public data as of September 2026.

Comparator acquisition costs are documented. Medicare Part B payment limits effective July 1 to September 30, 2026, based on first-quarter 2026 ASP data, were $743.605 per 1 mg for aflibercept (J0178), $298.683 per 1 mg for aflibercept 8 mg (J0177), $803.255 per 1 mg for aflibercept-ayyh (Q5147), $32.381 per 0.1 mg for faricimab (J2777), $51.090 per 0.1 mg for ranibizumab (J2778), $359.713 per 1 mg for brolucizumab (J0179), and $74.823 per 10 mg for bevacizumab (J9035), each with 20% coinsurance. Calculated at labeled doses for neovascular AMD, these limits correspond to $1,487.21 per aflibercept 2 mg injection, $2,389.46 per aflibercept 8 mg injection, $1,942.86 per faricimab 6 mg injection, $255.45 per ranibizumab 0.5 mg injection, and $2,158.28 per brolucizumab 6 mg injection. Reported 2025 wholesale acquisition costs (WAC) per injection were $2,677.50 for aflibercept 8 mg and $2,289.65 for faricimab. In 2025, Medicare Part B spending across all indications was $2,378,138,734 for faricimab (213,777 beneficiaries), $1,537,858,049 for aflibercept 2 mg (222,280 beneficiaries), $1,140,248,051 for aflibercept 8 mg (99,161 beneficiaries), and $522,266,027 for the aflibercept biosimilar aflibercept-ayyh (80,140 beneficiaries); the nine branded and biosimilar ophthalmic anti-VEGF codes reported, which exclude bevacizumab, totaled approximately $5.67 billion. From 2014 to 2023, Medicare beneficiaries received 36,398,293 intravitreal anti-VEGF injections, and standardized Medicare reimbursement per injection fell from $1,527.37 to $1,379.54 for aflibercept and from $1,234.35 to $724.74 for ranibizumab.

Cost-effectiveness evidence exists only for comparators. Over 5 years from a United States payer perspective, faricimab dominated aflibercept 2 mg, yielding 2.80 QALYs for $52,797 versus 2.72 QALYs for $62,367 with 22.6 versus 34 injections, and had a 97% probability of being cost-effective at $100,000 per QALY; under an every-8-week faricimab regimen the incremental cost-effectiveness ratio was $162,175 per QALY. A model using 2025 wholesale acquisition costs estimated total 3-year costs for aflibercept 8 mg that were $1,978.74 lower than for faricimab in neovascular AMD, with 12.25 versus 14.80 injections. For the port delivery system with ranibizumab, the incremental cost-utility ratio versus ranibizumab injections was $75,497 per QALY at 1 year, $304,108 per QALY at 5 years, and $761,646 per QALY at 12 years, and a Medicare cost analysis found break-even at 10.8 ranibizumab, 9.3 aflibercept, or 34.5 bevacizumab injections in the first year against a 1-year port delivery system cost of $21,016. In an 11-year cost-utility analysis, aflibercept was not cost-effective compared with bevacizumab ($1,151,451 per QALY incremental), and average ophthalmic cost-utility ratios were $11,033 per QALY for bevacizumab, $44,801 per QALY for aflibercept, and $79,600 per QALY for ranibizumab.

One published United States analysis addresses the value of a one-time anti-VEGF gene therapy directly. A discounted cash flow model estimated the present value of a single treatment replacing lifelong injections at $208,420.61 versus aflibercept, $219,093.31 versus ranibizumab, and $17,379.41 versus bevacizumab, varying from $78,323.19 to $292,449.87 by age at first injection and from $148,422.91 to $388,096.81 by injection frequency; the authors argued that bevacizumab should be the base case and that reimbursement mechanisms should include contingencies for sustained efficacy. The only marketed precedent for a one-time ocular gene therapy is voretigene neparvovec, whose wholesale acquisition cost was set at $425,000 per dose or per eye in January 2018, distributed through both buy-and-bill and a direct-to-payer contracting model, with outcomes-based rebates tied to short-term efficacy at 30 to 90 days and durability at 30 months and a proposal to CMS for payments over time.

4D-150 is an investigational one-time intravitreal AAV gene therapy that expresses aflibercept and a microRNA targeting VEGF-C from the evolved R100 capsid, so it is intended to replace repeated anti-VEGF injections rather than to extend the interval between them. It is not approved in any country, no biologics license application or other marketing application has been announced, and its regulatory standing consists of FDA regenerative medicine advanced therapy designation for wet AMD granted in December 2023 and EMA PRIME designation granted in October 2023. Phase 3 design was aligned with the FDA under RMAT designation and with the EMA and the Japan Pharmaceuticals and Medical Devices Agency, using noninferiority margins of 4.5 letters for the FDA and approximately 4 letters elsewhere.

Evidence maturity is early relative to the claim being made. Seventy-one participants have received the phase 3 dose across the phase 1/2 PRISM trial, and the only randomized comparison against an active control is a 24-week analysis of 51 participants in which the BCVA difference versus aflibercept had a confidence interval spanning -7.6 to 4.1 letters. The results that carry the durability claim, a 78% reduction in injections at 2 years in 30 participants and 87% in the 15-participant recently diagnosed subgroup, come from an open-label single-arm cohort in which burden was measured against a modeled on-label aflibercept schedule rather than against observed comparator injections. The evidence gap is therefore both large and direct: no randomized phase 3 result exists, and the registration trials (523 participants randomized in 4FRONT-1 and more than 500 expected in 4FRONT-2) test noninferiority of BCVA change at 52 weeks with supplemental aflibercept permitted in both arms and randomization restricted to participants with a documented anatomic response to aflibercept during a run-in, so they are designed to show comparable vision with fewer injections in a selected population, not superior vision. Topline 52-week data are expected in the second quarter of 2027 and the second half of 2027.

Safety signals reported so far are limited but reassuring within the size of the dataset. Intraocular inflammation occurred in 2 of 71 participants (2.8%) at the phase 3 dose, was graded 1+ and transient, and no new cases were reported with 2 to more than 4 years of follow-up; no 4D-150-related hypotony, endophthalmitis, vasculitis, retinal vascular occlusion, or choroidal effusion has been observed, and no 4D-150-related serious adverse events have been reported. All participants received an approximately 20-week prophylactic topical corticosteroid taper, and 70 of 71 (99%) remained off steroids afterward. A sample of 71 participants cannot exclude uncommon events, adverse event frequency tables have not been published, and class considerations for AAV therapy remain, including vector-directed immune responses, pre-existing neutralizing antibodies to the capsid, and the irreversibility of a one-time treatment. Inflammation risk in this class appears dose- and route-dependent: about 23% of participants in an early suprachoroidal ABBV-RGX-314 cohort had mild inflammation, and inflammation with ixoberogene soroparvovec led to selection of a lower dose with topical-only prophylaxis.

The comparator is effective but imperfectly delivered. Intravitreal anti-VEGF therapy is first-line treatment in the AAO Preferred Practice Pattern, with labeled maintenance intervals from every 4 weeks for ranibizumab to every 8 to 16 weeks for aflibercept 8 mg; participants completing 96 weeks in PULSAR received a mean of 8.2 to 12.8 injections, and through 2 years in TENAYA and LUCERNE the median was 10 faricimab injections versus 15 for aflibercept. In routine United States care, a mean of 7.3 injections in the first year produced a mean gain of 0.95 letter across 49,485 treatment-naive eyes, 2,003 of 9,007 patients (22.2%) were lost to follow-up, and up to 50% of patients stopped treatment by 24 months; at 5 years in CATT, mean acuity was 3 letters below baseline and 11 letters below the 2-year value. Existing options that reduce visit frequency carry their own risks, including a boxed warning for an up to 3-fold higher rate of endophthalmitis with the surgically implanted port delivery system and labeled warnings for retinal vasculitis and retinal vascular occlusion with brolucizumab. Anti-VEGF therapy is paid under Medicare Part B, where ranibizumab and aflibercept were reported to account for 12% of the annual Part B budget.

For a pharmacy and therapeutics committee, 4D-150 is not a formulary decision in 2026, and the practical question is what evidence to require when phase 3 data arrive. What remains unknown is whether noninferior vision with reduced injections is confirmed in a randomized trial; whether the effect persists beyond 2 years, since registered outcomes extend only to week 104 and long-term follow-up is planned through year 5; whether results generalize to aflibercept non-responders, patients with longer disease duration or extensive prior treatment, central subfield thickness above 500 µm, or pre-existing neutralizing antibodies to the capsid; whether redosing or fellow-eye treatment is feasible; and what the product will cost, since no price, coverage policy, cost-effectiveness analysis, or budget impact model exists. Until a price is disclosed, the comparison that determines value, a single administration against a lifetime of injections that carry Medicare Part B payment limits of roughly $255 to $2,389 per injection at labeled doses, cannot be made.